T-Therapeutics Raises $133M Series B to Push TCR Therapies Into Clinics

T-Therapeutics has raised $133 million in an oversubscribed Series B round to push two first-in-class TCR-CD3 bispecific therapy programs into clinical development. The Cambridge, UK-based biotech drew heavyweight strategic money: the round was co-led by Advent Life Sciences and British Business Bank, with Johnson & Johnson Innovation – JJDC, Samsara BioCapital, M-Ventures and Eli Lilly and Company participating. Existing major shareholders Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures, Tencent and BGF also backed the raise.

The figure is large by UK biotech standards and buys a specific milestone: both programs — one in oncology, one in immunology — are funded through clinical proof-of-concept. That is a promise of data, not of approved drugs, and the gap between the two remains where most T-cell programs historically fail.

What makes the platform's claim different?

T-Therapeutics builds medicines on T cell receptors that recognize proteins associated with disease. Its proprietary OpTiMus platform generates fully human TCRs, aimed at targets that conventional medicines have historically failed to reach. The lead oncology program targets solid tumors, a field where existing T cell engager technologies have struggled because suitable targets are scarce. The immunology program takes a different angle: it aims to selectively eliminate disease-causing cells tied to chronic inflammation, potentially offering more precise immune modulation.

Advent Life Sciences General Partner Dominic Schmidt framed the bet bluntly: "T cell engagers have delivered clinical success in hematological cancers but have been held back in solid tumors by the lack of appropriate targets. By unlocking previously undruggable intracellular targets, with the potential for a markedly improved safety profile, T-Therapeutics' platform brings the promise of this treatment/modality to solid tumors, where the great majority of cancers arise."

Note the hedging in that quote: "potential" for a better safety profile, "promise" of the modality. Neither has been demonstrated in humans yet by these programs.

Who is running the clinical push?

Alongside the financing, T-Therapeutics appointed Dr. Kirsty Crame as Chief Development Officer. Crame brings more than 15 years of biopharmaceutical development experience and previously served as Chief Medical Officer at Curatis. She also held senior clinical development roles at Medigene and Gadeta, where she worked on early-stage therapeutic programs, including TCR-based treatments. At T-Therapeutics she will oversee translational research and clinical development as the programs move toward human studies.

Crame said: "I am delighted to join T-Therapeutics at this pivotal moment for the Company. I look forward to advancing our clinical strategy and first-in-class programs, and to realizing the potential of our platform technologies to address major therapy areas with significant unmet patient need."

The company is also expanding its board. Representatives from Advent Life Sciences, British Business Bank, JJDC and Samsara BioCapital will join as non-executive directors — a governance footprint that matches the four newest investors and signals their long-term involvement.

What did the CEO actually commit to?

CEO Theodora Harold made the strongest claim in the announcement: "This financing is a key step in our transition to a clinical-stage company, enabling us to accelerate the development of two oncology and immunology programs with pan-indication, blockbuster potential, underpinned by a platform that reaches targets long considered undruggable. The further strengthening of our team with the appointment of Dr. Kirsty Crame, and the proceeds from this raise, position us well for rapid execution of those programs and the delivery of important clinical proof-of-concept data."

"Blockbuster potential" is a valuation claim about drugs that have not yet entered human trials. The verifiable commitment is narrower: the $133 million carries both programs to proof-of-concept readouts.

The round gives T-Therapeutics the balance sheet to make that transition, but investors' returns now hinge on clinical data the company has yet to generate. Watch for first-in-human trial filings and the safety profile of its solid-tumor program — the two numbers that will test Schmidt's thesis.